Abstract
Objective
Lianhuaqingwen and Shuanghuanglian are drug treatment options for Corona Virus Disease 2019 (COVID-19). In China, use of traditional Chinese medicine with Shuanghuanglian or Lianhuaqingwen (for them, forsythiaside is the active antiviral and antibacterial component) in combination with azithromycin is common for the treatment of pediatric pneumonia. It is important to understand the reason why the combination of these compounds is better than a single drug treatment. This study aimed to explore the pharmacokinetic interaction between forsythiaside and azithromycin.
Methods
Twelve male Sprague-Dawley rats were randomly divided into an experimental group (Forsythia suspensa extract and azithromycin) and a control group (a single dose of Forsythia suspensa extract in 5% glucose solution). Plasma samples were collected at scheduled time points, and the high-performance liquid chromatography combined with ultraviolet method was used to determine the plasma forsythiaside concentration. Non-compartmental analysis and population pharmacokinetic methods were used to investigate the forsythiaside pharmacokinetic difference between the experimental and control group.
Results
Compared with a single administration, the area under the curve and half-life of forsythiaside increased, and forsythiaside clearance decreased significantly after co-administration with azithromycin. The in vivo behavior of forsythiaside could be described by the one compartment model. The forsythiaside clearance decreased when combined with azithromycin. Visual evaluation and bootstrap results suggested that the final model was precise and stable.
Conclusion
Co-administration of azithromycin can significantly decrease the forsythiaside clearance and increase drug exposure. A lower dose of azithromycin can obtain sufficient forsythiaside concentration to provide antiviral and antibacterial activity.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Runfeng L, Yunlong H, Jicheng H, et al. Lianhuaqingwen exerts anti-viral and anti-inflammatory activity against novel coronavirus (SARS-CoV-2). Pharmacol Res, 2020,156:104761
Wang L, Xu X, Ruan J, et al Quadruple therapy for asymptomatic COVID-19 infection patients. Expert Rev Anti Infect Ther, 2020,18(7):617–624
Lu H. Drug treatment options for the 2019-new coronavirus (2019-nCoV). Biosci Trends, 2020,14(1): 69–71
Ni L, Zhou L, Zhou M, et al Combination of western medicine and Chinese traditional patent medicine in treating a family case of COVID-19. Front Med, 2020,14(2):210–214
Wang F, Cao GS, Li Y, et al Characterization of forsythoside A metabolites in rats by a combination of UHPLC-LTQ-Orbitrap mass spectrometer with multiple data processing techniques. Biomed Chromatogr, 2018,32(5):e4164
Zhang S, Shao SY, Song XY, et al Protective effects of Forsythia suspense extract with antioxidant and anti-inflammatory properties in a model of rotenone induced neurotoxicity. Neurotoxicology, 2016,52:72–83
Wu ZQ, Liu GH, Yan LJ, et al. Experimental study on anti-influenza virus infection with yinqiao-decoction by orthogonal design. Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi (Chinese), 2010,24(6):427–429
Zeng XY, Yuan W, Zhou L, et al Forsythoside A exerts an anti-endotoxin effect by blocking the LPS/TLR4 signaling pathway and inhibiting Tregs in vitro. Int J Mol Med, 2017,40(1):243–250
Law AH, Yang CL, Lau AS, et al Antiviral effect of forsythoside A from Forsythia suspensa (Thunb.) Vahl fruit against influenza A virus through reduction of viral M1 protein. J Ethnopharmacol, 2017,209:236–247
Qu H, Zhang Y, Wang Y, et al Antioxidant and antibacterial activity of two compounds (forsythiaside and forsythin) isolated from Forsythia suspensa. J Pharm Pharmacol, 2008,60(2):261–266
Bakheit AH, Al-Hadiya BM, Abd-Elgalil AA. Azithromycin. Profiles Drug Subst Excip Relat Methodol, 2014,39:1–40
Ma WG, Jia JM, The effects and prospects of the integration of traditional Chinese medicine and Western medicine on andrology in China. Asian J Androl, 2011,13(4):592–595
Lampe H, Halle B, Freund M. Western and Chinese medicine in oncology and hematology. Forsch Komplementmed, 2011,18(4):185–191
Zhang C, Wang Y, Zhao X, et al. Prediction of Recurrent Stroke or Transient Ischemic Attack After Noncardiogenic Posterior Circulation Ischemic Stroke. Stroke, 2017,48(7):1835–1841
Qing GC, Zhang H, Bai Y, et al. Traditional Chinese and Western Medicines Jointly Beat COVID-19 Pandemic. Chin J Integr Med, 2020,26(6):403–404
Ren JL, Zhang AH, Wang XJ. Traditional Chinese medicine for COVID-19 treatment. Pharmacol Res, 2020,155:104743
Yang Y, Islam MS, Wang J, et al. Traditional Chinese Medicine in the Treatment of Patients Infected with 2019-New Coronavirus (SARS-CoV-2): A Review and Perspective. Int J Biol Sci, 2020,16(10):1708–1717
Liu N, Chen X, Yin L. Clinical effect of azithromycin sequential therapy combined with shuanghuanglian oral solution on pediatric mycoplasma pneumonia and the impact on serum inflammatory cytokines levels and immunologic function. Pract J Cardiac Cereb Pneum Vasc Dis, 2016,24(9):94–97
Wang H. Efficacy of shuanghuanglian oral liquid only for children combined with azithromycin in the treatment of mycoplasma pneumonia in children. Chin Foreign Med Res, 2018,16(7):25–27
Tian J, Sun S, Zhao Z, et al. Pharmacokinetic interaction between shuanghuanglian and azithromycin injection: a nonlinear mixed-effects model analysis in rats. Xenobiotica, 2019,49(11):1344–1351
Tian JC, Lin LF, Li XC, et al. Forsythiaside stability in pretreated rat plasma and its pharmacokinetics after i.v. administration. Anal Methods-Uk, 2015,7(5):1809–1815
Wang H, Li X, Sun S, et al. Population Pharmacokinetics and Dosing Simulations of Ceftazidime in Chinese Neonates. J Pharm Sci, 2018,107(5):1416–1422
Hooker AC, Staatz CE, Karlsson MO. Conditional weighted residuals (CWRES): a model diagnostic for the FOCE method. Pharm Res, 2007,24(12):2187–2197
Zhang L, Yu J, Zhou Y, et al. Becoming a Faithful Defender: Traditional Chinese Medicine against Coronavirus Disease 2019 (COVID-19). Am J Chin Med, 2020,48(4):763–777
Li T, Lu H, Zhang W. Clinical observation and management of COVID-19 patients. Emerg Microbes Infect, 2020,9(1):687–690
Ho LTF, Chan KKH, Chung VCH, et al. Highlights of traditional Chinese medicine frontline expert advice in the China national guideline for COVID-19. Eur J Integr Med, 2020,36:101116
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
The authors declare that there is no conflict of interest with any financial organization or corporation or individual that can inappropriately influence this work.
Additional information
This project was supported by the Natural Science Foundation of Beijing Municipality (No. 7192060).
Rights and permissions
About this article
Cite this article
Tian, Jc., Zhang, Xl., Cui, Jr. et al. Impact of Azithromycin on Forsythiaside Pharmacokinetics in Rats: A Population Modeling Method. CURR MED SCI 42, 863–870 (2022). https://doi.org/10.1007/s11596-022-2596-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11596-022-2596-2